RNA vs BCAX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 09, 2026

RNA

52.5
AI Score
VS
BCAX Wins

BCAX

65.8
AI Score

Investment Advisor Scores

RNA

53score
Recommendation
HOLD

BCAX

66score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RNA BCAX Winner
Net Income -36.82M -111.65M RNA
Operating Income -39.90M -120.19M RNA
ROE -17.2% -23.8% RNA
ROA -13.1% -21.8% RNA
Total Assets 280.51M 512.24M BCAX
Cash 72.33M 96.60M BCAX
Current Ratio 8.73 11.59 BCAX
Free Cash Flow -37.20M -81.83M RNA

Relative Price Performance (Last 90 Days)

RNA 1M: -14.9% · 3M: -16.7% BCAX 1M: -7.4% · 3M: +7.2%

Current Technical Phase

RNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 31

RSI (14): 31.2 · Price: $10.36

BCAX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 39

RSI (14): 39.5 · Price: $22.81

Fundamentals Snapshot

Metric RNA BCAX
Market Cap
Forward P/E -1.3 -6.6
Trailing P/E
Revenue (TTM)
Revenue Growth -0.2% 0.0%
Gross Margin -0.6%
Operating Margin -7.5% 0.0%
EPS -5.36 -3.00
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, BCAX is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.